Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta-Analysis
Nolan Reinisch1, Athena Mancini1, Adham Elsherbini1
1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Movement Disorders Clinical Practice
|May 4, 2026
Summary
Homogenous cell transplantation offers meaningful motor improvements for Parkinson's disease (PD) patients, particularly when medication is off. This investigational strategy shows a favorable safety profile in open-label studies.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Clinical Trials
Background:
- Parkinson's disease (PD) management is exploring cell transplantation as an alternative to symptomatic treatments.
- Homogenous cell transplantation is an investigational strategy for PD.
Purpose of the Study:
- To systematically review and meta-analyze the clinical efficacy and safety of homogenous cell transplantation in Parkinson's disease.
- Assess the impact of homogenous cell transplantation on motor function and safety in PD patients.
Main Methods:
- Systematic review and meta-analysis of clinical trials identified through MEDLINE, EMBASE, and Cochrane Library searches.
- Inclusion of studies with defined homogenous cell populations, validated outcomes, and extractable data.
- Synthesis of continuous measures using mean differences (MD) under fixed- or random-effects models; risk of bias assessed using Cochrane methodology.
Main Results:
- Twenty studies (374 patients) met criteria; 14 contributed to pooled analyses.
- Significant, durable motor improvements (UPDRS scores) observed in the OFF state at multiple time points (3-24 months), with benefits attenuating after 36 months.
- Dopaminergic progenitor and retinal pigment epithelial grafts showed beneficial responses; adverse events were generally mild and transient.
Conclusions:
- Homogenous cell transplantation is associated with meaningful and durable motor improvements in Parkinson's disease patients, especially in the OFF state.
- The procedure demonstrates a favorable safety profile, with generally mild and transient adverse events.
- Cell transplantation represents a promising therapeutic avenue for Parkinson's disease.
More Related Videos
06:09Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis
Published on: February 2, 2021
3.9K
09:21Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
Published on: July 7, 2023
2.1K
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
01:22iPS Cell Differentiation
2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K